If you have been reading about NR1D2 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-27. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
=== Oxidative addition === Oxidative addition to the 14-electron Pd(0) complex is proposed. This process gives a 16-electron Pd(II) species. It has been suggested that anionic ligands, such as OAc, accelerate this step by the formation of [Pd(OAc)(PR3)n]−, making the palladium species more nucleophillic. In some cases, especially when an sp3-hybridized organohalide is used, an SN2 type mechanism tends to prevail, yet this is not as commonly seen in the literature. However, despite normally forming a cis-intermediate after a concerted oxidative addition, this product is in rapid equilibrium with its trans-isomer.
In Portal, the player controls the protagonist, Chell, from a first-person perspective as she navigates a series of test chambers using the Aperture Science Handheld Portal Device, commonly known as the portal gun, under the supervision of the artificial intelligence GLaDOS. The portal gun can create two distinct portal ends, blue and orange, which connect different locations within the test chambers. The portals form a connection between two points in three-dimensional space, allowing Chell and objects to pass between them. Neither portal functions exclusively as an entrance or exit, as objects entering one emerge from the other. The game's physics preserve an object's momentum as it passes through a portal, while its trajectory is determined by the orientation of the exit portal. A common maneuver involves placing one portal below the player, falling through it to gain speed, and emerging from another portal positioned on a wall or other surface. This technique allows the player to redirect momentum and launch Chell or objects across gaps and other obstacles. The technique is commonly referred to as "flinging". When portal surfaces are positioned at different orientations, the player's orientation changes when passing through them so that the character remains aligned with the game's gravitational direction. Chell and objects that fit through the portal openings can pass between them, while portals cannot be fired through an existing open portal. Portals cannot be placed on moving objects, glass, certain surfaces, liquids, or areas that are too small to accommodate them.
== Medical uses == Relugolix is approved in the United States, Canada and the United Kingdom for the treatment of prostate cancer, in Japan for the treatment of uterine fibroids (uterine leiomyoma) and in the United Kingdom for endometriosis.
Sources: en.wikipedia.org
==== Medal of the Royal Victorian Order (RVM) ==== In Silver John Nelson Hart, Gamekeeper, Sandringham Estate. Keith Hodson, Stud Hand, Royal Studs. Constable Anthony Claud James, Royalty and Diplomatic Protection Department, Metropolitan Police. John Trodden Kerr, Leading Palace Attendant, Windsor Castle. Leading Marine Engineering Mechanic (Mechanical) Andrew Kevin King, HM Yacht Britannia. Richard Clive Lines, Painter, Sandringham Estate. Musician William Huw Morris, HM Yacht Britannia. Sergeant Paul Andrew George Murrell, Norfolk Constabulary. Peter Leonard Riches, Foreman Gardener, Crown Estate, Windsor. Constable Mervyn John Shrubb, Royalty and Diplomatic Protection Department, Metropolitan Police. David Wetherill, Sacristan, St George's Chapel, Windsor Castle. John Herbert Willison, lately of Truefitt & Hill Limited. Acting Petty Officer Marine Engineering Mechanic (Electrical) Barry John Winstone, HM Yacht Britannia.
A common belief among users is that the smoke of a hookah (waterpipe, narghile) is significantly less dangerous than that from cigarettes. The water moisture induced by the hookah makes the smoke less irritating and may give a false sense of security and reduce concerns about true health effects. Doctors at institutions including the Mayo Clinic have stated that use of hookah can be as detrimental to a person's health as smoking cigarettes, and a study by the World Health Organization also confirmed these findings. Although the smoking effects are similar to a cigarettes, due to the manner in which a hookah is utilized, smoking hookah may potentially absorb a higher amount of toxic substances, compared to cigarette smokers. Each hookah session typically lasts more than 40 minutes, and consists of 50 to 200 inhalations that each range from 0.15 to 0.50 liters of smoke. In an hour-long smoking session of hookah, users consume about 100 to 200 times the smoke of a single cigarette; A study in the Journal of Periodontology found that water pipe smokers were marginally more likely than regular smokers to show signs of gum disease, showing rates 5-fold higher than non-smokers rather than the 3.8-fold risk that regular smokers show. A systematic review on waterpipe smoking and cancer reports that waterpipe smokers had significantly higher, up to six times odds of lung cancer compared to non-smokers. A study on hookah smoking and cancer in Pakistan was published in 2008. Its objective was "to find serum CEA levels in ever/exclusive hookah smokers, i.e.
=== Other uses in science and technology === AAA battery, a standard size of dry cell battery Angle-angle-angle, a method for identifying similar triangles in geometry Area activity analysis, a quality tool for process management American Anthropological Association Australian Archaeological Association Airdrie Astronomical Association, an astronomy club and registered charity in North Lanarkshire, Scotland
where ζ is the potential across the Stern layer (zeta potential), E is the electric field strength, and η is the viscosity of the solvent. Separation of components in CEC is based on interactions between the stationary phase and differential electrophoretic migration of solutes.
Sources: en.wikipedia.org
=== Views on homosexuality === Jung addressed homosexuality in his published writings, in one comment specifying that homosexuality should not be a concern of legal authorities nor be considered a crime. He also stated that homosexuality does not reduce the value of a person as a member of society. Jung also said that homosexuality is a result of psychological immaturity ("nurture"), but only if one's sexuality is not an aspect of their constitutional characteristics ("nature").
While photosystem II photolyzes water to obtain and energize new electrons, photosystem I simply reenergizes depleted electrons at the end of an electron transport chain. Normally, the reenergized electrons are taken by NADP+, though sometimes they can flow back down more H+-pumping electron transport chains to transport more hydrogen ions into the thylakoid space to generate more ATP. This is termed cyclic photophosphorylation because the electrons are recycled. Cyclic photophosphorylation is common in C4 plants, which need more ATP than NADPH.
The term "Holstein" derives from Old Saxon Holseta Land (Holz means wood in modern Standardized German; holt is a now-archaic English word for woods.) Originally, the term referred to the central of the three Saxon tribes north of the River Elbe: Tedmarsgoi (Dithmarschen), Holstein, and Sturmarii (Stormarn). The area inhabited by the tribe of the Holsts lay between the Stör River and Hamburg; after Christianization, their main church was in Schenefeld. Saxon Holstein became a part of the Holy Roman Empire after Charlemagne's Saxon campaigns in the late eighth century. Beginning in 811, the northern border of Holstein (and thus of the Empire) was the River Eider. The term "Schleswig" originally referred to the city of Schleswig. The word Schleswig is a German transliteration of the Danish word Slesvig, which consists of two words: Schlei and vig. The Schlei refers to the river at which the city lies, and vig means "inlet" or bay. Schleswig, therefore, means (in Danish): "The bay at the river Schlei". The Schlei is known as Slien in Danish and is believed to have been used only for the inner Slien (the Great and Little Bay near the city of Schleswig). The word is thought to be related to Slæ, which means reeds and aquatic plants found in this area. The Duchy of Schleswig, or Southern Jutland, was originally an integral part of Denmark, but in medieval times was established as a fief under the control of the Kingdom of Denmark, having the same relationship with the Danish Crown as, for example, Brandenburg or Bavaria had with the Holy Roman Emperor.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.